Aspruzyo Sprinkle Disease Interactions
There are 3 disease interactions with Aspruzyo Sprinkle (ranolazine).
Ranolazine (applies to Aspruzyo Sprinkle) severe hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Plasma concentrations of ranolazine increased by 30% in patients with mild (Child-Pugh Class A), and by 60% in patients with moderate (Child-Pugh B) hepatic impairment. The use of ranolazine is contraindicated in patients with clinically significant hepatic impairment.
References
- (2006) "Product Information. Ranexa (ranolazine)." Calmoseptine Inc
Ranolazine (applies to Aspruzyo Sprinkle) QT prolongation
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome
Ranolazine prolongs the QT interval in a dose-related manner. Caution should be exercised if used in patients with long QT interval, or using other QT- prolonging drugs.
References
- (2006) "Product Information. Ranexa (ranolazine)." Calmoseptine Inc
Ranolazine (applies to Aspruzyo Sprinkle) renal disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
In patients with varying degrees of renal impairment, ranolazine plasma levels increased up to 50%, Caution is advised when used in patients with renal impairment. The pharmacokinetics of ranolazine has not been assessed in patients on dialysis.
References
- (2006) "Product Information. Ranexa (ranolazine)." Calmoseptine Inc
Aspruzyo Sprinkle drug interactions
There are 525 drug interactions with Aspruzyo Sprinkle (ranolazine).
Aspruzyo Sprinkle alcohol/food interactions
There is 1 alcohol/food interaction with Aspruzyo Sprinkle (ranolazine).
More about Aspruzyo Sprinkle (ranolazine)
- Aspruzyo Sprinkle consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: antianginal agents
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.